Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

Introducing Tenable Hexa AI: The Agentic Engine That Supercharges Security Productivity and Accelerates Risk Reduction

View original at globenewswire.com
Introducing Tenable Hexa AI: The Agentic Engine That Supercharges Security Productivity and Accelerates Risk Reduction SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) -- RSA Conference Booth at #6155 — Tenable® Holdings, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Tenable Exposure Data Fabric is the industry's most comprehensive repository of contextualized exposure data and intelligence

    60% confidence
  • Tenable protects over 40,000 customers around the globe

    60% confidence
  • Tenable Hexa AI marries an agentic orchestration engine to the powerful contextual exposure data fabric of Tenable One, automating complex tasks and orchestrating fixes across the enterprise, neutralizing exposures before they're exploited.

    60% confidence
  • There has never been a greater need to have an agentic system preemptively fixing issues before they are exploited. As AI-based attacks accelerate, the window from discovery to exploitation has effectively vanished.

    60% confidence
  • Tenable Hexa AI has fundamentally shifted how we deploy our security resources, powering and scaling efficiency across workflows. Reclaiming two days a month on a single process like asset tagging is a massive win for our team.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com